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Aim of the study: The diffusion capacity of the lung for carbon monoxide (DLCO) is
an important tool in the diagnosis and follow-up of patients with pulmonary diseases.
In case of a decreased DLCO the KCO, defined as DLCO/VA (VA is alveolar volume), can
differentiate between normal alveolocapillary membrane (normal KCO) and
abnormal alveolocapillary membrane (low KCO). The latter category consists of
decreased surface of the membrane, increased thickness or decreased perfusion of
ventilated alveoli. The VA/TLC (TLC is total lung capacity determined by whole body
plethysmography) can partially differentiate between these categories. The aim of
this study was to investigate the diagnostic value of the specific diffusion
disturbances, which can be constructed by combining the DLCO, KCO and VA/TLC.
Methods: In 460 patients the diagnosis made by clinicians were fitted into five
diagnostic categories: asthma, chronic obstructive pulmonary disease (COPD), treat-
ment effects of haematologic malignancies, heart failure and diffuse parenchymal lung
diseases (DPLD). These categories were linked to the pattern of diffusion disturbance.
Results: Almost all patients with asthma have a normal DLCO, most patients in the
other groups do not have the expected pattern of diffusion disturbance, especially in
the group with DPLD a bad match is observed.
Conclusion: In this study the pattern of diffusion disturbance is of limited use in
establishing a diagnosis. The use of the KCO next to the DLCO has no additional
diagnostic value. Regional ventilation–perfusion inequality probably forms an
important underlying mechanism of decreased DLCO.
& 2005 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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The diffusion capacity of the lung for carbon
monoxide (DLCO) is a standard test in the pulmonary
function laboratory. The DLCO is used in the
assessment of restrictive as well as obstructive
pulmonary diseases, and is an indicator of disease
severity. In chronic obstructive pulmonary disease
(COPD) and in diffuse parenchymal lung diseases
(DPLD) the DLCO is a strong predictor for desatura-
tion during exercise.1,2 Furthermore, the DLCO is an
important parameter in the assessment of response
to therapy in idiopathic pulmonary fibrosis (IPF)3
and other DPLD.
The KCO is defined as the DLCO/VA, where VA is the
alveolar volume: the KCO is often referred to as
‘‘DLCO corrected for VA’’, or the diffusion capacity
per litre lung volume. VA is measured by a single
breath helium dilution technique and is sensitive to
ventilatory disturbances. When VA is less than 85%
of TLC, as measured by whole body plethysmogra-
phy, ventilation inhomogeneity is considered to be
present.4 The discriminative properties of the VA/
TLC ratio only accounts for TLC measured with
whole body plethysmography, because then all air
containing parts of the thorax are measured (using
multiple breath helium dilution inaccessible parts
of the lungs are still not included).
In several publications5–7 a method of interpreta-
tion of diffusion disturbances has been proposed
based on the DLCO, KCO and VA/TLC ratio. When the
DLCO is decreased, the KCO locates the diffusion
abnormality at the level of the alveolocapillary
membrane or not. A low KCO indicates a situation
where the DLCO is decreased solely or where it is
decreased more than a lowered VA. Both phenom-
ena point to pathology at the level of the
alveolocapillary membrane. The cause can be a
decreased surface with ventilation inhomogeneityFigure 1 Commonly used algorithm in interpreting diffusing a
VA, VA/TLC is single breath helium dilution alveolar volume d
plethysmography.(e.g. emphysema), an increased thickness (fibrosis)
or a decreased perfusion of ventilated alveoli.
Using the VA/TLC ratio, emphysema can be
detected, due to the presence of ventilation
inhomogeneity, which leads to a low VA/TLC ratio.
In fibrotic disorders such ventilatory disturbances
are not present and therefore the VA/TLC ratio will
be normal.4 In case of a low DLCO and a normal KCO,
the decreased diffusion is due to a volume effect
(to a so-called small lung, as in lobectomy/
pneumectomy, chest cage restriction) or to the
presence of non-communicating air as in bullous
emphysema. The VA/TLC ratio again can discrimi-
nate between these possibilities: a low VA/TLC
ratio (o85%) indicates the presence of ventilation
inhomogeneity (bullous emphysema), a normal VA/
TLC ratio indicates a small lung syndrome or chest
cage restriction.
Most authors5 present algorithms as shown in
Fig. 1. Although these algorithms are meant to give
insight in the underlying pathology, and are easy to
understand, they have never been tested in clinical
practice, as far as we know. The aim of this study is
to test the clinical relevance of this scheme. We
investigated whether the clinical diagnosis and the
diffusion patterns as sketched above would match
sufficiently with emphasis on the discrimination
between COPD and DPLD.Methods
All new consecutive patients referred to the
pulmonary function laboratory between July 1999
and November 2002 were assessed. Only patients
who performed DLCO, spirometry and whole body
plethysmography on the same day were included in
this study. From patients who underwent PFT more
than once, only the entry test was used.bnormalities. DLCO is corrected for anaemia, KCO is DLCO/
ivided by total lung capacity determined by whole body
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Diffusion pattern versus diagnosis 103Pulmonary function data
Plethysmography, spirometry and the diffusion
tests were carried out according to ERS guide-
lines8,9 using a bodyplethysmograph (Jaeger Mas-
terlab) and a Jaeger Masterscreen FRC system by
qualified lung function technicians. Upon arrival,
patients routinely rest for 15min before any lung
function test was determined, while whole body
plethysmography was always performed immedi-
ately before spirometry. Diffusing measurements
were made after spirometry, but before reversi-
bility testing. The DLCO measurement was per-
formed based on ATS recommendations,10 which
include refraining from smoking for 24 h before the
test (to minimise CO backpressure), and all DLCO
values are corrected to standard haemoglobin of
14.6 g/dl for men and 13.4 g/dl for women (to rule
out anaemia effects). For reversibility testing, all
patients received salbutamol 200 mg pMDI via
Volumatic and after 15min, spirometry was re-
peated.
Measured variables were single breath DLCO, VA,
DLCO/VA, TLC, residual volume, forced expiratory
volume in 1 s (FEV1), (forced) vital capacity, peak
flow, maximum expiratory flow at 25%, 50% and 75%
of expiration.
In the pulmonary function, laboratory daily
quality control procedures were performed as
recommended by the European Respiratory So-
ciety.8,9Patterns of diffusion disturbance
For the DLCO and KCO, the actual measured value
was expressed as a percentage of the predicted
value: a value outside the 95% confidence interval
was labelled as abnormal.9 The VA/TLC is defined as
the single breath helium dilution VA, as determinedTable 1 Description of the diagnostic groups.
Group Description
Asthma According to ATS gu
COPD According to ATS gu
Treatment effects of
haematological malignancies
Malignant lymphom
leukaemia’s, multip
including treatmen
Heart failure Diagnosed by exper
cardiologists
DPLD Diffuse parenchyma
(DPLD) as defined b
criteria15with the DLCO measurement, divided by the TLC
determined by plethysmography. We used the 85%
cut off point proposed by Cotes4 to separate normal
from diseased.
We defined five categories (Fig. 1): category 0 is
no diffusion disturbance (not shown in figure),
meaning a normal DLCO; category I is a low DLCO, a
low KCO and VA/TLC o0.85; category II is a low
DLCO, a low KCO and VA/TLC40.85; category III is a
low DLCO, normal KCO and VA/TLC o0.85 and
category IV is a low DLCO, normal KCO and VA/
TLC40.85.Diagnostic categories
All patients were seen by experienced pulmonary
physicians, who took a case history, performed a
physical examination, reviewed a chest X-ray and
assessed all pulmonary function data including
flow-volume curves.
We defined the following diagnostic categories:
asthma, COPD, treatment effects of haematologi-
cal malignancies, heart failure and DPLD (Table 1)
and defined the corresponding diffusion patterns.
The diagnosis of asthma was based on clinical
assessment with typical symptoms, PFT including
reversibility testing in all patients and bronchial
provocation testing with histamine in most pa-
tients, the measurement of eosinophilic leuco-
cytes, total and specific IgE antibodies.11 The
expected diffusion pattern is category 0.
The diagnosis of COPD was mainly based on
clinical assessment including smoking history, radi-
ology and spirometry, and the exclusion of other
obstructive pulmonary diseases.11,12 The expected
diffusion pattern of the COPD group is category I
and III.
The group of treatment effects of haematologi-
cal malignancies includes different haematologicalExpected diffusion pattern
idelines11 No diffusion abnormality
idelines11 Abnormal ventilation
a, all
le myeloma,
t effects
Abnormal alveolo-capillary
membrane, normal ventilation
ienced Abnormal alveolo-capillary
membrane, normal ventilation
l lung diseases
y ATS/ERS
Abnormal alveolo-capillary
membrane, normal ventilation
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I. van der Lee et al.104malignancies as described in Table 1 and their
various treatments. Chemotherapy often leads to
lowering of the diffusion capacity, whereas thoracic
radiotherapy leads to restriction.13 Therefore the
expected diffusion pattern is category II, and
category IV (if the lowering of the DLCO is only
due to restriction).
Heart failure patients suffer from irreversible
diseased alveolocapillary membranes14 and reduc-
tion of lung size, due to the enlarged heart, which
will direct the subjects to a category II.
In all patients with DPLD15 the diagnosis was
made after intensive clinical assessment, radiolo-
gical investigations including high resolution com-
puted tomography scanning in all patients, PFT
including exercise testing, bronchoscopy with
bronchoalveolar lavage in most patients, transbron-
chial or thoracoscopic lung biopsy whenever in-
dicated, and consultation of any other medical
specialist (for example cardiologists and rheuma-
tologists) when indicated. The expected diffusion
pattern in this group is category II.
We reviewed the charts of all patients in order to
confirm the accuracy of the diagnosis, and excluded
patients with diagnostic dilemmas. Exclusion cri-
teria were as follows: patients in which the
clinician could not differentiate between two
diagnosis (i.e. asthma or COPD), patients with
more than one diagnosis from the categories and
patients who could not be fitted into any of the
categories.Results
Initially 639 patients were reviewed, after the
exclusion of patients that did not fit the inclusion
criteria 460 patients remained: 208 females and
252 males. Most of the excluded patients had moreTable 2 Pulmonary function tests results.
# Age FEV1%pred TLC %pre
Asthma 188 45 (15) 89 (18) 104 (13)
COPD 143 62 (11) 64 (17) 114 (15)
Treatment effects
of hematologic
malignancies
49 43 (12) 74 (19) 78 (16)
Heart failure 21 50 (16) 72 (20) 82 (17)
DPLD 59 50 (15) 71 (18) 74 (14)
Total 460 51 (16) 77 (21) 100 (20)
Clinical diagnosis versus number of patients (]), mean age (stand
mean TLC determined by plethysmography as percentage predict
corrected for hemoglobin as percentage predicted (SD), mean KCOthan one diagnosis from the list of categories. Mean
age was 51 years, ranging from 18 to 88. A selection
of the PFT data is displayed in Table 2. The overall
mean DLCO was 67% of the predicted value: patients
with asthma had the highest DLCO. The lowest mean
KCO was seen in the COPD group, followed by the
heart failure and DPLD groups. The group of asthma
patients had highest FEV1, as expected. The
diagnosis of COPD was made in 143 patients, 132
of these had a FEV1/FVC ratio o70%. In seven out
of 59 patients from the DPLD group a FEV1/FVC
ratio o70% was observed.
The relation of the clinical diagnosis to the
patterns of diffusion disturbance is shown in Table
3: the majority of the patients with asthma had a
normal DLCO, and of those with a lowered DLCO
most had a normal KCO.
Within the COPD subjects a minority (18%) of
those with a lowered DLCO had a normal KCO and
were hence labelled as category III: most showed a
ventilation inhomogeneity. Within the lowered KCO
group 34% showed a VA/TLC ratio485% and were
placed in category II. An emphysematous diffusion
pattern (combining category I and III) is present in
54% of the COPD cases, in those with a lowered
DLCO (n ¼ 109) 71% of the COPD patients show a
‘‘correct’’ pattern. On the other hand, of the 142
subjects with an emphysema pattern only 77 were
true emphysema subjects: in 54% the diffusion
pattern correctly denotes emphysema.
Of the subjects with DPLD with a lowered DLCO,
59% had a normal KCO and hence a large minority, a
lowered one. In the latter group 40% of cases
showed a lowered VA/TLC ratio and therefore were
incorrectly labelled with emphysema. In the end,
only 12 out of 59 DPLD subjects showed ‘the
correct’ fibrotic diffusion pattern (category II).
Both heart failure and haematological malig-
nancy subjects showed highly variable patterns
with a preference for category II and IV.d FEV1/FVC
%
DLCO
%pred
KCO %pred VA/TLC
76 (10) 84 (17) 90 (14) 91 (8)
57 (11) 56 (21) 62 (22) 82 (10)
83 (7) 59 (22) 81 (21) 92 (8)
84 (10) 54 (17) 74 (15) 89 (10)
80 (11) 51 (18) 79 (23) 89 (11)
72 (15) 67 (24) 78 (22) 88 (10)
ard deviation (SD)), mean FEV1 as percentage predicted (SD),
ed (SD), mean FEV1/FVC ratio as percentage (SD), mean DLCO
as percentage predicted (SD), mean VA/TLC as percentage (SD).
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Table 3 Diagnostic groups versus pattern of diffusion disturbance.
Category 0 Category I Category II Category III Category IV Total
Asthma 126 1 4 21 36 188
COPD 34 57 30 20 2 143
Treatment effects of haematologic malignancies 12 3 12 6 16 49
Heart failure 2 2 7 3 7 21
DPLD 10 8 12 12 17 59
Total 184 71 65 62 78 460
Table 4 Categories of diffusion disturbance in patients with DPLD.
Category 0 Category I Category II Category III Category IV Total
IPF 0 3 0 2 1 6
Sarcoidosis 8 1 3 4 6 22
COP 0 2 0 1 1 4
Col-vasc disease 0 0 5 2 7 14
Fibrosis n.c. 2 2 4 3 2 13
Total 10 8 12 12 17 59
DPLD is diffuse parenchymal lung diseases, IPF is idiopathic pulmonary fibrosis, COP is cryptogenic organizing pneumonia, col-
vasc disease is DPLD associated with collagen vascular disease, fibrosis n.c. means non-classified.
Diffusion pattern versus diagnosis 105The group of subjects with DPLD is very hetero-
geneous: we retrieved all diagnosis from the
patients’ charts and related it to the diffusion
patterns (Table 4). Again, a bad match is observed
between the specific fibrotic disorders and the
diffusion pattern. IPF is mostly seen as an arche-
type of fibrotic lung disease, but none of the six
subjects with IPF has the expected fibrotic diffusion
pattern (category II).Discussion
We investigated whether an interpretation scheme
of diffusion patterns would indeed render a reliable
clinical diagnosis. The match between the sug-
gested patterns and the clinical diagnosis cannot be
considered as sufficiently close for the diagnostic
scheme to be used satisfactorily in daily practice.
There are several possible explanations for this
observation. The first one is that our disease
categories were not well defined. However, pa-
tients with more than one diagnosis were excluded:
concomitant pulmonary disease is hence very
improbable, which eliminates much overlap and
maximises the inclusion of classical disease pat-
terns. Cardiologists of course made the initial
diagnosis of heart failure after echocardiography:all heart failure patients were referred to the lung
function laboratory as part of the standard cardi-
ological work up. The exclusion of pre-existing
severe pulmonary disease renders the possibility of
isolated right heart failure low. All patients with
haematological disorders were seen and referred
by haematologists, because of possible pulmonary
effects of the treatment and disease itself.
There is no absolute dividing line between the
diagnosis asthma and COPD. Almost all (92%)
patients with COPD have a FEV1/FVCo70%, hence
we feel that not many diagnostic mistakes were
made in that group. Some asthmatics may truly be
COPD-patients, which could account for the 12% (22
out of 188) of emphysematous diffusion patterns
(category I and III) in this group.
Of course, the possibility that technical mistakes
with pulmonary function testing were made must
also be kept in mind. If that was to be the sole
cause of the noted discrepancies, at least 30% of
the measurements must have been flawed. We feel
that is too far fetched, taking into account the
daily quality control procedures and the vast
experience of the technicians.
We observed that in subjects with DPLD appar-
ently a lowered DLCO and a normal KCO is quite
standard and this must mean that the lowering of
VA and DLCO were of similar magnitude. Taking this
argument one step further: a lowered KCO is not so
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I. van der Lee et al.106common. Some may be tempted to judge the pre/
absence of disease by just assessing the KCO.
According to this study this approach is incorrect:
most patients will be missed. Another finding is that
VA/TLC ratioso85% are quite common in DPLD. The
most probable explanation for this phenomenon is
the existence of ventilation abnormalities in some
of the patients in the DPLD group, not assumed to
be present and easily obscured by the fibrotic
process. DPLD is a very heterogeneous group of lung
diseases and sometimes smoking related, for
example IPF. So, when someone is diagnosed with
IPF it is possible that some co-existing and indis-
tinct obstructive disease is present which leads to
the low VA/TLC ratio. The obstruction is not
detectable via spirometry and/or body plethysmo-
graphy. It is well known that cryptogenic organizing
pneumonia (COP) as well as sarcoidosis can lead to
airway obstruction, so it would be incorrect to label
these patients with a second diagnosis of COPD.
From this group only seven patients (12%) have
FEV1/FVCo70%, three patients with sarcoidosis,
two with COP and two with fibrosis of unknown
cause.
In the COPD group a normal KCO is much less
common than in the DPLD group. Again, a normal
KCO does not exclude disease, because most of
these subjects showed a significant degree of
ventilation inhomogeneity, labelling these subjects
with bullous emphysema. Unfortunately, in 30 of
the 87 COPD subjects with a lowered DLCO and KCO,
the VA/TLC is485% and hence the pattern suggests
fibrosis. We examined the characteristics of these
30 subjects: 11 male and 19 female, mean age 56,
mean FEV1 is 74% of predicted, mean TLC 110%
predicted, mean FEV1/FVC is 61% of predicted. It
appeared that 26 of them have FEV1/FVCo70% and
when reviewing the charts none of these patients
had diagnostic controversies. In these 30 subjects
the possibility exists that the pathophysiological
phenomenon responsible for the decreased KCO is
thickening of the membranes, but we think that is
very unlikely: in none of the patients the radi-
ological studies are compatible with fibrosis. There-
fore, it is likely that non-perfusion of ventilated
alveoli (ventilation–perfusion inequality) is the
cause of the lowered KCO. With the available data
we cannot further investigate this hypothesis,
because invasive investigations are necessary, but
regional ventilation–perfusion inequality is an im-
portant cause of diffusion limitation as earlier
investigators described.16 Of course this pattern
could also be found with pulmonary embolism,17
but after reviewing the patients’ charts in none of
the cases strong arguments for the existence of
pulmonary embolism were present, although it wasnot formally excluded using ventilation–perfusion
scintigraphy.
In this study almost all included patients with
heart failure show a decreased DLCO, which has
been described earlier.18 These patients did not
show a specific diffusion pattern and hence may be
categorised variably. Of course, subtle pulmonary
abnormalities in these groups can explain some of
these differences, bearing in mind that many
patients with heart failure are former smokers.
The category of treatment effects of haemato-
logical malignancies is heterogeneous. All patients
in this category received chemotherapy, which is
known to cause a reduction of the diffusing
capacity.13,19 Moreover, patients with haematologic
malignancies treated with high dose chemotherapy
can often develop serious pulmonary diseases,
which can give different pulmonary syndromes
(e.g. bronchiolitis obliterans and graft-versus-host
disease can lead to a modest restriction and
lowering of the DLCO
20). Some patients received
concomitant radiotherapy, which can have additive
effects on pulmonary function, mostly leading to
restriction.13 Furthermore, subtle smoking-induced
abnormalities can lead to a lowered VA/TLC, which
can obscure other treatment effects.Accuracy of model
A possible explanation for the weak correlation
between the disease categories and the diffusion
patterns is that the model is incorrect. It is possible
that the pathophysiology underlying diffusion ab-
normalities is much more complicated than this
rather simple model. The distinction between DLCO
and KCO plays an important role in this model. In
the calculation of KCO (DLCO/VA, Fig. 2) the term VA
is used in the numerator and in the denominator. In
the numerator, VA is used to transform gas volume
into moles of gas. In the denominator the VA is
expressed in litres of gas volume, so there are two
ways of looking at the value of KCO. The first and
most used way is to see the KCO as DLCO corrected
for VA, the second way as the rate constant of
exponential decay of alveolar CO concentration,
because the VA in the numerator and in the
denominator cancel each other out.21 The fact
that the KCO is not simply a parameter that
describes the diffusion per unit lung volume
obscures this model, i.e. it makes the model more
difficult to understand. Others have observed the
lack of clinical relevance of the KCO next to the
DLCO in the recent past.
22
Another important factor is that the TLC as
percentage predicted is not incorporated in this
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Figure 2 The equation of the single breath KCO, in which t is breath hold time, PB is barometric pressure, PH2O is water
vapour pressure, F0,CO is fractional alveolar [CO] at time 0, Ft,CO fractional alveolar [CO] at time t, VA is alveolar
volume. KCO can be expressed in two ways: as DLCO/VA and as the exponential decay in alveolar [CO] multiplied by
constant c.
Diffusion pattern versus diagnosis 107model. Pulmonologists know that the TLC is an
important parameter in the assessment of espe-
cially restrictive pulmonary diseases. From this
study it can be derived that the VA/TLC ratio cannot
replace the TLC parameter.
Another possible weakness in this model is that
the group of subjects with low DLCO, low KCO and
normal VA/TLC ratio is heterogeneous, and contains
thickening of the alveolocapillary membrane and
non-perfusion of ventilated areas. A distinction
between these two cannot be made with this
scheme. Ventilation–perfusion relationships have
a major effect on gas-exchange.23 The fact that
postural changes24,25 and gravitational changes26
affect the DLCO is based on alterations in the
regional ventilation–perfusion relationship. In sub-
jects with obstructive as well as restrictive pul-
monary diseases the regional ventilation–perfusion
relationship contributes to impaired diffusion.16
Therefore the measurement of the DLCO is closely
related to the relationship of pulmonary ventilation
and perfusion. As Roughton and Forster showed in
1957,27 the DLCO is composed of the alveolocapil-
lary membrane conductance (Dm) and of the
product of the pulmonary capillary blood volume
(Vcap) and yCO (the rate of carbon monoxide uptake
by whole blood). Until now it still is unclear which
proportions of Dm and Vcap are determining the
DLCO measurement
28 in various pulmonary diseases.
Of course it is possible to calculate a value for Dm
and Vcap with the high/low oxygen method
27 or
with the NO (nitric oxide)-CO method29,30 in
subjects with pulmonary diseases. However, the
Roughton and Forster model is a mono-alveolar
model, therefore the distinction between thicken-
ing of the alveolocapillary membranes on the one
hand and ventilation–perfusion inequality on the
other hand cannot be made with the division of the
DLCO in Dm and Vcap.Reference values
This model is strongly dependent on accurate
reference values for the DLCO and KCO. Concerning
the KCO, an ongoing debate exists whether the
reference values are of much use.31,32 The mainproblem lies in the fact that the regression
equations for KCO simply do not exist: it is common
practice to divide the reference value for DLCO by
the reference value of the TLC.9 These two
reference values are obtained from different
populations, which of course is not an ideal
situation. Furthermore, KCO is calculated as DLCO
divided by VA, instead of DLCO divided by TLC. The
reason for this is merely historical, and used overall
in Europe and North America. Because VA is the
single breath helium dilution measurement, VA is
lower than TLC, especially in obstructive pulmon-
ary diseases, where the VA/TLC ratio can drop to far
below 85%. Therefore, in obstructive pulmonary
diseases, the use of VA instead of TLC leads to
higher values of KCO, and therefore a higher
percentage of patients in the category ‘‘normal
KCO’’. Another issue concerning the reference
values compasses the fact of the dependence of
KCO on VA. In healthy patients, the KCO rises if the VA
decreases, as Stam et al.33 determined some years
ago. Indications are present that this phenomenon
is also present in patients with restrictive pulmon-
ary diseases.34 If true, this means that for patients
with a restriction, the reference values for the KCO
should be higher. In that case the flow chart leading
to the fibrotic diffusion pattern (category II) will be
more complicated. Although some investigators
found ways of recalculating the KCO by using
adjusted VA values,
32,34–36 this has never been
adopted by clinicians on a broad scale.
The cut-off value for VA/TLC ratio we used was
85%. This rather arbitrary value is based on
recommendations of Cotes,4 who on his turn based
it on earlier publications, which are hard to trace
back. The value of 85% is assuming an exact
dividing line between normal and disturbed venti-
lation, which of course is not the case, in fact there
is a continuous scale between normal and disturbed
ventilation. This could explain the percentage of
39% (56 out of 143) patients with COPD and normal
VA/TLC ratio. The finding of decreased DLCO with
relative undisturbed ventilation in patients with
COPD has been described earlier.37
In conclusion, the measurement of the DLCO is of
utmost importance in the assessment of the gravity
of different pulmonary diseases, and it has an
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I. van der Lee et al.108important value in assessing the response to
treatment in DPLD. However, the simple diagnostic
flow chart used in some publications has limited
value in establishing a diagnosis. The use of the KCO
next to the DLCO has no additional diagnostic value,
and therefore a normal KCO can never rule out
major pulmonary pathology. The DLCO should be
used as a tool in the diagnosis, assessment and
follow-up of patients, but a diagnosis can never be
based on diffusion disturbance only.References
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